Impella® Heart Pump and Reduced Occurrence of Acute Kidney Injury in High-Risk PCI

October 24, 2017

Dr. Michael Flaherty discusses the retrospective, single-center study published in Circulation Research which finds that use of hemodynamic support with Impella 2.5® heart pump during high-risk percutaneous coronary intervention (HRPCI) can reduce the risk of acute kidney injury (AKI) even when those patients had preexisting kidney disease and low ejection fraction (EF). The new study builds upon earlier data from PROTECT II, a randomized clinical trial, which found kidney injury rates were numerically lower when more contrast was used during HRPCI, and adds to the growing body of evidence of the benefits of hemodynamic support with Impella during HRPCI.

Related Content

Subscribe or join the conversation by following us on Twitter: @ProtectedPCI


To learn more about the Impella® platform of heart pumps, including important risk and safety information associated with the use of the devices, please visit: